表皮生长因子受体相关靶向治疗与肺癌的研究进展  

Research progress of EGFR related targeted therapy and pulmonary carcinoma

作　　者：王丹云[1] 彭忠民[2] 

机构地区：[1]山东大学附属济南市中心医院普胸外科,250013 [2]山东大学附属省立医院普胸外科,250021

出　　处：《中华胸部外科电子杂志》2017年第1期56-62,共7页CHINESE JOURNAL OF THORACIC SURGERY：Electronic Edition

摘　　要：近年来,非小细胞肺癌(NSCLC)的治疗进展主要以分子靶向治疗为主导地位。依据组织和分子学类型制定个体化治疗方案已成为靶向治疗时代的准则,表皮生长因子受体(EGFR)基因是目前肺癌众多驱动基因中研究最多、证据最充分、了解最透彻的一个分子靶点。表皮生长因子酪氨酸激酶抑制剂(EGFR-TKI)已广泛应用于EGFR突变的NSCLC。该文将EGFR相关靶向药物在NSCLC的治疗进展做一综述。During the past several years,advances in the treatment of non-small cell lung cancer（NSCLC） have predominantly involved the development of therapies directed at molecular targets.Treatment based on histology andmolecular characterization has become a guideline of care in the era of targeted therapy. Among numerous driver genes of NSCLC, epidermal growth factor receptor （EGFR） gene is one molecular target concerning with most researches, abundant evidences and thoroughunderstandings. Epidermal growth factor tyrosine kinase inhibitor（ EGFR-TKI） has been widely used in the treatment of NSCLC haboring EGFR mutation. This review provides an overview of gene related targeted therapies in NSCLC.

关 键 词：非小细胞肺癌 肺腺癌 表皮生长因子受体 分子靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]